Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
If AlzeCure-developed ACD680 reached the market, it would deepen Eli Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.
Read the full article on the original site.
Read Full Article